TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18032884
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder dissolved in water (CC-W)
Study: 18032884
Drug: Cocoa powder
Normalized name: Cocoa powder
DrugBank: Cocoa (DB10977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa powder dissolved in milk (CC-M)
Study: 11784454
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg daily for 12 weeks)
Study: 23624993
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 12 weeks)
Study: 12209299
Drug: Lichtenstein patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lichtenstein patch
Study: 3061823
Drug: Cisplatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (60 mg/mq i.v. every 3 weeks) + 5‐fluorouracil (600 mg/mq i.v. bolus/weekly)
Study: 26218236
Drug: PREG-LT (Pregnenolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREG-LT (Pregnenolone 50 mg/day + L-Theanine 400 mg/day)
Study: 27701170
Drug: Beta-blockers (BBs)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (BBs) at baseline
Study: 27701170
Drug: Ceftriaxone (intravenous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (intravenous, 2 g per day for 4 days)
Study: 23995395
Drug: Post-treatment (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (3 months after acute phase)
Study: 19020155
Drug: Ketamine (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (infusion of 15 microg x kg(‐1) x min(‐1))
Study: 19020155
Drug: Ketamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine and fentanyl (infusion of 15 microg x kg(‐1) x min(‐1) ketamine plus three bolus of 1 microg x kg(‐1) fentanyl)
Study: 19020155
Drug: Lornoxicam (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (one bolus of 8 mg)
Study: 19020155
Drug: Lornoxicam and
Normalized name: Lornoxicam and paracetamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam and fentanyl (one bolus of 8 mg lornoxicam plus three bolus of 1 microg x kg(‐1) fentanyl)
Study: 12036083
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 1 g/day
Study: 12036083
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 5 g/day
Study: 12036083
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid 10 g/day
Study: 10602891
Drug: 5FU/LMS therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU/LMS therapy
Study: 7549345
Drug: 0.25% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% timolol in Gelrite administered once daily (TG)
Study: 7549345
Drug: 0.25% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% timolol solution administered twice daily (TS)
Study: 2202283
Drug: Scarlet ointment
Normalized name: scarlet red Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scarlet ointment dressing alone
Study: 2202283
Drug: Scarlet ointment
Normalized name: scarlet red Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scarlet ointment after bupivacaine
Study: 2202283
Drug: Scarlet ointment
Normalized name: scarlet red Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scarlet ointment
Study: 6972732
Drug: nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nalidixic acid (NA), 1 g every 6 h for 7 days
Study: 6972732
Drug: trimethoprim/sulfamethoxazole (TMP/SMZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim/sulfamethoxazole (TMP/SMZ), 160/800 mg every 12 h for 10 days
Study: 21438171
Drug: eFlow® nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: eFlow® nebulizer (100 mg/ml tobramycin solution, 1.5 ml)
Study: 21438171
Drug: PARI LC
Normalized name: Pari LC Pediatric Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARI LC PLUS® nebulizer (300 mg at 60 mg/ml tobramycin)
Study: 21438171
Drug: Tolerability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolerability of treatment
Study: 16167971
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg am and 20 mg pm for 7 days
Study: 12800605
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan (60 mg/m2 on days 1 and 8) plus carboplatin (AUC 4.0 on day 1, every 28 days)
Study: 12800605
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan (90 mg/m2 on days 1 and 8) plus carboplatin (AUC 2.0 on days 1 and 8, every 21 days)
Study: 10233192
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg AM + Ranitidine 150 mg HS
Study: 10233192
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. AC
Study: 6811217
Drug: Short-course chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course chemotherapy (rifampicin, isoniazid, ethambutol until sensitivity tests completed, then isoniazid alone for four months)
Study: 6811217
Drug: Two-year chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-year chemotherapy scheme (rifampicin, isoniazid, ethambutol until culture conversion, then isoniazid alone for two years)
Study: 25926350
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg Novaferon injected 3 times per week
Study: 25926350
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg Novaferon injected twice per week
Study: 25926350
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg Novaferon injected 3 times per week
Study: 23332861
Drug: VI 25
Normalized name: VITRAKVI 25mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: VI 25 μg
Study: 17712588
Drug: Pergolide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (mean dose 2.93 ± 0.75 mg per day, range 0.75 to 5 mg)
Study: 17712588
Drug: Pergolide (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (mean dose 2.93 ± 0.75 mg per day)
Study: 15856361
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg daily (n=12)
Study: 15856361
Drug: Anastrozole 1
Normalized name: anastrozole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole 1 mg twice weekly (n=11)
Study: 12424712
Drug: Interferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa‐2b (3 million units subcutaneously three times weekly) plus ribavirin (800 to 1,000 mg/d) for 12 months
Study: 10482176
Drug: Cariporide (HOE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariporide (HOE 642) 40 mg intravenous bolus prior to reperfusion
Study: 1755159
Drug: Lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoic acid administered in complex with tyrosine catabolism cofactors (pyridoxal phosphate, ascorbic acid, iron ions)
Study: 28926857
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet with potassium supplementation (4.5 g/day, KCl)
Study: 19281935
Drug: IV hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV hydromorphone (0.0075 mg/kg)
Study: 19281935
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine (0.05 mg/kg)
Study: 821802
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral typhoid vaccine from the German Democratic Republic (GDR)
Study: 821802
Drug: Killed oral
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed oral typhoid vaccine from the German Federal Republic (GFR)
Study: 821802
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group for GDR vaccine)
Study: 821802
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group for GFR vaccine)
Study: 29509918
Drug: Unchanged L‐T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged L‐T4 dose
Study: 29509918
Drug: Higher L‐T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher L‐T4 dose
Study: 29509918
Drug: Lower L‐T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower L‐T4 dose
Study: 26437957
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg/daily
Study: 26437957
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg/daily
Study: 22741474
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine decoction (supplementing qi and nourishing yin recipe)
Study: 22741474
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine decoction
Study: 22741474
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine decoction and Medroxyprogesterone acetate
Study: 16044002
Drug: CD4-guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD4-guided treatment
Study: 16044002
Drug: Week-on-week-off treatment
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Week-on-week-off treatment
Study: 8620717
Drug: Lisinopril (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (four daily doses)
Study: 1954354
Drug: High-dose Ara‐C
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Ara‐C (3 g/m2 IV over 1 h every 12 h eight times followed by 25 mg/m2 per day daunorubicin IV bolus for 2 days)
Study: 1954354
Drug: Conventional consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional consolidation therapy (200 mg/m2 of behenoyl‐arabino‐furanosylcytosine for 7 days and 25 mg/m2 of daunorubicin for 2 to 3 days)
Study: 6184493
Drug: Warfarin sodium
Normalized name: Warfarin Sodium
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin sodium
Study: 29905630
Drug: Stimulation (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation (n = 7) for 30 minutes after initial treatment.
Study: 20171597
Drug: Tetrathiomolybdate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetrathiomolybdate therapy
Study: 18572080
Drug: Aciclovir 400
Normalized name: Aciclovir 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 400 mg twice daily (n=1637)
Study: 18572080
Drug: Aciclovir 400
Normalized name: Aciclovir 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir 400 mg twice daily
Study: 12452026
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of warm (43 degrees C‐45 degrees C) distilled water (1,250 ml/m2) plus 5‐fluorouracil (500 mg/L) after radical gastrectomy
Study: 12452026
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of warm (43 degrees C‐45 degrees C) distilled water (1,250 ml/m2) plus 5‐fluorouracil (500 mg/L) before operation
Study: 18565240
Drug: Patient preference
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient preference for treatment
Study: 1486900
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (e.g. furosemide 40 mg, torasemide 5 and 10 mg)
Study: 1486900
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (muzolimine 20 mg, torasemide 2.5 mg)
Study: 1486900
Drug: Thiazide-type diuretics
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide-type diuretics (e.g. hydrochlorothiazide 25 and 50 mg, xipamide 10, 20 and 40 mg)
Study: 2428187
Drug: Aggregation inhibitors,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggregation inhibitors, low heparin dosage, and preoperative normovolaemic haemodilution
Study: 30928824
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (110 or 150 mg bid, plus clopidogrel or ticagrelor)
Study: 30928824
Drug: Dabigatran dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran dual therapy (110 or 150 mg)
Study: 25686117
Drug: Pre‐emptive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐emptive treatment
Study: 20142600
Drug: Reactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive treatment
Study: 23921857
Drug: Prophylactic ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prophylactic ibuprofen (800 mg starting 1 hour before misoprostol, then every 4-6 hours for 48 hours regardless of pain)
Study: 23921857
Drug: Therapeutic ibuprofen
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic ibuprofen (800 mg every 4-6 hours as needed for pain)
Study: 23921857
Drug: Therapeutic ibuprofen
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic ibuprofen
Study: 19879035
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus oral azathioprine for 24 months (AZA group)
Study: 19879035
Drug: Prednisone plus
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone plus intravenous cyclophosphamide pulses (CIC group)
Study: 18379360
Drug: I 160
Normalized name: CI 16035
Approvals — FDA: no, EMA: no, PMDA: no
Description: I 160 mg/m(2) plus D 60 mg/m(2) on day 1 every 21 days (arm A)
Study: 18379360
Drug: I 80
Normalized name: Ambi 80/780
Approvals — FDA: no, EMA: no, PMDA: no
Description: I 80 mg/m(2) on days 1,8 plus D 60 mg/m(2) on day 1 every 21 days (arm B)
Study: 18379360
Drug: I 60
Normalized name: CI 60725
Approvals — FDA: no, EMA: no, PMDA: no
Description: I 60 mg/m(2) plus D 30 mg/m(2) on days 1, 8, 15, and 22 every 42 days (arm C)
Study: 16601869
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid (DHA) administration (25 mg/kg per day, divided into three daily doses)
Study: 14617464
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron dextran
Study: 8814046
Drug: Medication severity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication severity rating
Study: 1403033
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of doxorubicin and cyclophosphamide with vincristine and prednisone followed by 1 year of leukocyte alpha-interferon
Study: 1403033
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of doxorubicin and cyclophosphamide with vincristine and prednisone
Study: 1403033
Drug: Doxorubicin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin administered by continuous infusion
Study: 23422453
Drug: Vibration therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration therapy (twice a week for 3 months)
Study: 15725968
Drug: Atomoxetine (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.2 mg/kg/day)
Study: 20525942
Drug: Atomoxetine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5 mg/kg/day)
Study: 1646290
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan
Study: 15097434
Drug: HL-450 (AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-450 (AR milk thickened with 0.45 g/100 mL LBG)
Study: 15097434
Drug: HL-350 (AR
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL-350 (AR milk with reduced concentration of 0.35 g/100 mL LBG)
Study: 8613331
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml BCG vaccine at birth
Study: 8613331
Drug: 0.05 ml
Normalized name: xenon 0.05 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 ml BCG vaccine at birth
Study: 8613331
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml BCG vaccine at 4-6 weeks
Study: 8613331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.1 ml BCG at birth)
Study: 1091940
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg during detoxification
Study: 1091940
Drug: Propranolol 20
Normalized name: propranolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 20 mg during detoxification
Study: 1091940
Drug: Propranolol 10
Normalized name: propranolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 10 mg given 2 hrs before 30 mg morphine i.v.
Study: 1091940
Drug: Placebo (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control) given 2 hrs before morphine
Study: 28716230
Drug: Interferon β-1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon β-1a injected subcutaneously three times weekly (IFN β‐1a SC tiw)
Study: 28716230
Drug: Interferon β-1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon β-1a injected intramuscularly once weekly (IFN β‐1a IM qw)
Study: 17710008
Drug: EMLA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (5 g)
Study: 17710008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neomycin ointment 5 g)
Study: 15596745
Drug: IV immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV immunoglobulins (IVIg) 1 g/kg
Study: 11516593
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment (smoking cessation intervention initiated two weeks after admission)
Study: 11516593
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (smoking cessation intervention initiated six weeks after admission)
Study: 7833096
Drug: MACC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC chemotherapy
Study: 7833096
Drug: MACC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC chemotherapy + Lonidamine (LND) 150 mg orally three times daily
Study: 7833096
Drug: MACC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC chemotherapy + LND
Study: 7833096
Drug: MACC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACC chemotherapy (control)
Study: 3240760
Drug: Lignocaine jelly
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine jelly and spray combination
Study: 3240760
Drug: Lignocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine spray alone
Study: 31230007
Drug: Methadone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone plus daily placebo dose-extension (PDE)
Study: 31230007
Drug: Methadone/treatment as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone/treatment as usual (control)
Study: 25875868
Drug: Study vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study vaccine (trivalent, inactivated split influenza vaccine)
Study: 25875868
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (commercially available trivalent, inactivated split influenza vaccine)
Study: 21545398
Drug: aliskiren/HCTZ 150/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: aliskiren/HCTZ 150/12.5 mg, titrated to 300/25 mg
Study: 21545398
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg, titrated to 10 mg
Study: 16215314
Drug: Urethral injection
Normalized name: Urethral Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urethral injection of 100 units of botulinum A toxin (n=20)
Study: 16215314
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment as controls (n=10)
Study: 9988956
Drug: Aggressive antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive antihypertensive treatment to achieve a goal diastolic blood pressure of 80 mm Hg or lower
Study: 1976875
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/day
Study: 7767417
Drug: Ibuprofen syrup
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen syrup (5 mg/kg per dose)
Study: 7767417
Drug: Acetaminophen syrup
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen syrup (10 mg/kg per dose)
Study: 2252040
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg twice a day)
Study: 2252040
Drug: Erythromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (400 mg four times a day)
Study: 7018669
Drug: Non-BCG treatment
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-BCG treatment
Study: 23823808
Drug: Pre-ERCP somatostatin
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-ERCP somatostatin (0.5 mg/h for 24 hours, starting 1 hour prior to ERCP)